These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15107600)

  • 1. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease.
    Põder P; Eha J; Antila S; Heinpalu M; Planken U; Loogna I; Mesikepp A; Akkila J; Lehtonen L
    Cardiovasc Drugs Ther; 2003; 17(5-6):451-8. PubMed ID: 15107600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects.
    Sundberg S; Lehtonen L
    Eur J Clin Pharmacol; 2000; 55(11-12):793-9. PubMed ID: 10805056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
    Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.
    Sundberg S; Lilleberg J; Nieminen MS; Lehtonen L
    Am J Cardiol; 1995 May; 75(15):1061-6. PubMed ID: 7747690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
    Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
    Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamic dose-efficacy of levosimendan in healthy volunteers.
    Lilleberg J; Sundberg S; Häyhä M; Akkila J; Nieminen MS
    Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects.
    Lehtonen L; Sundberg S
    Eur J Clin Pharmacol; 2002 Oct; 58(7):449-52. PubMed ID: 12389066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure.
    Põder P; Eha J; Sundberg S; Antila S; Heinpalu M; Loogna I; Planken U; Rantanen S; Lehtonen L
    Int J Clin Pharmacol Ther; 2003 Aug; 41(8):365-73. PubMed ID: 12940594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin.
    Antila S; Jarvinen A; Honkanen T; Lehtonen L
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):705-10. PubMed ID: 11214780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
    Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
    Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
    Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting.
    Lilleberg J; Nieminen MS; Akkila J; Heikkilä L; Kuitunen A; Lehtonen L; Verkkala K; Mattila S; Salmenperä M
    Eur Heart J; 1998 Apr; 19(4):660-8. PubMed ID: 9597417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery.
    Mehta RH; Leimberger JD; van Diepen S; Meza J; Wang A; Jankowich R; Harrison RW; Hay D; Fremes S; Duncan A; Soltesz EG; Luber J; Park S; Argenziano M; Murphy E; Marcel R; Kalavrouziotis D; Nagpal D; Bozinovski J; Toller W; Heringlake M; Goodman SG; Levy JH; Harrington RA; Anstrom KJ; Alexander JH;
    N Engl J Med; 2017 May; 376(21):2032-2042. PubMed ID: 28316276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of levosimendan during long-term amiodarone treatment in dogs.
    Papp JG; Pollesello P; Varró A; Végh A; Udvary E
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):27-32. PubMed ID: 16867167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term levosimendan treatment improves systolic function and myocardial relaxation in mice with cardiomyocyte-specific disruption of the Serca2 gene.
    Hillestad V; Kramer F; Golz S; Knorr A; Andersson KB; Christensen G
    J Appl Physiol (1985); 2013 Nov; 115(10):1572-80. PubMed ID: 24072410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
    Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.